Benchmark Upgrades Emergent BioSolutions (EBS) to Buy, 'NARCAN OTC Gains Nod'
Tweet Send to a Friend
(Updated - April 10, 2023 6:19 AM EDT)
Benchmark analyst Robert Wasserman upgraded Emergent BioSolutions (NYSE: EBS) from Hold ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Benchmark analyst Robert Wasserman upgraded Emergent BioSolutions (NYSE: EBS) from Hold ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
